Editas Medicine Employee Directory
Biotechnology ResearchMassachusetts, United States51-200 Employees
Editas Medicine is a clinical-stage biotechnology company focused on genome editing therapies designed to repair broken genes. It pursues CRISPR/Cas9 and CRISPR/Cas12a approaches to build a pipeline of treatments for serious diseases. Headquartered in Cambridge, Massachusetts, the company aims to discover, develop, manufacture, and commercialize precision genomic medicines for a broad range of conditions. The organization operates as a research-driven enterprise advancing programs from discovery through development. In the biotechnology field, Editas sits at the intersection of genome editing and therapeutic development, with the goal of delivering durable genomic medicines to patients worldwide. Its work targets individuals living with serious diseases who may benefit from genome editing. In 2026, the company disclosed preclinical data for EDIT-401, its lead in vivo candidate for hyperlipidemia, presented at the European Atherosclerosis Society Congress.